Transforming and ontogenic potential of activated c-Ha-ras in three immortalized human breast epithelial cell lines

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4387-4394

  Wang, Biao ^a,c   Soule, Herbert D ^a,c   Miller, Fred R ^a,b,c  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Breast; MCF 10; MCF 12; ras; Transformation

Indexed keywords

AGAR; MUTANT PROTEIN; PROTEIN P21; HRAS PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST EPITHELIUM; CARCINOGENESIS; CELL CULTURE; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL TRANSFORMATION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE ACTIVATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE C H RAS; PHENOTYPE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; XENOGRAFT; ANIMAL; BIOSYNTHESIS; BREAST; BREAST TUMOR; CELL DIVISION; CELL LINE; GENETIC TRANSFECTION; GENETIC VARIABILITY; ONCOGENE RAS; PATHOLOGY; POLYMERASE CHAIN REACTION;

ANIMALS; BREAST; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FEMALE; GENES, RAS; HUMANS; MICE; MICE, NUDE; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS P21(RAS); RECOMBINANT PROTEINS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; VARIATION (GENETICS);

EID: 0031283133     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, Wagenaar SS, van Bodegom PC, Bos JL: Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 48: 5738-5741, 1988.
2. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554, 1988.
3. Bos JL, Fearon ER, Hamilton SR, de Vries MV, van Boom JH, van der Eb AJ, Vogelstein B: Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293-297, 1987.
4. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M: Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327: 298-303, 1987.
5. Kraus MH, Yuasa Y, Aaronson SA: A position 12-activated H-ras oncogene in all HS578T mammary carcinosarcoma cells but not in normal mammary cells of the same patient. Proc Natl Acad Sci U.S.A. 81: 5384-5388, 1984.
6. Kozma SC, Bogaard ME, Buse K, Saurer SM, Bos JL, Groner B, Hynes NE: The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB-231. Nucleic Acids Res 15: 5963-5971, 1987.
7. Rochlitz CF, Scott GK, Dodson JM, Liu E, Dollbaum C, Smith HS, Benz CC: Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res 49: 357-360, 1989.
8. Prosperi M, Dupre G, Lidereau R, Goubin G: Point mutation at codon 12 of the K-ras gene in a primary breast carcinoma and the MDA-MB-134 human mammary carcinoma cell line. Cancer Lett 57: 169-174, 1990.
9. Clark GJ, Der CJ: Aberrant function of the ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 35: 133-144, 1995.
10. Horan Hand P, Thor A, Wunderlich D, Muraro R, Caruso A, Schlom J: Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. Proc Natl Acad Sci U.S.A. 81: 5227-5231, 1984.
11. De Bartoli M, Abou-Issa H, Haley BE, Cho-Chung YS: Amplified expression of p21 ras protein in hormone-dependent mammary carcinomas of humans and rodents. Biochem Biophys Res Commun 127: 699-706, 1985.
12. Clair T, Miller WR, Cho-Chung YS: Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer. Cancer Res 47: 5290-5293, 1987.
13. Querzoli P, Marchetti E, Bagni A, Marzola A, Fabris G, and Nenci I: Expression of p21 ras gene product in breast cancer relates to histological type and to receptor and nodal status. Breast Cancer Res Treat 12: 23-30, 1988.
14. Dati C, Muraca R, Tazartes O, Antoniotti S, Perroteau I, Giai M, Cortese P, Sismondi P, Saglio G, De Bortoli M: c-erbB-2 and ras expression levels in breast cancer are correlated and show a cooperative association with unfavorable clinical outcome. Int J Cancer 47: 833-838, 1991.
15. Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ: Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 221: 706-718, 1995.
16. Ohuchi N, Thor A, Page DL, Horan Hand P, Halter SA, Schlom J: Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues. Cancer Res 46: 2511-2519, 1986.
17. Spandidos DA: Oncogene activation in malignant transformation: a study of H-ras in human breast cancer. Anticancer Res 7: 991-996, 1987.
18. Agnantis NJ, Mahera H, Maounis N, Spandidos DA: Immunohistochemical study of ras and myc oncoproteins in apocrine breast lesions with and without papillomatosis. Eur J Gynaecol Oncol 13: 309-315, 1992.
19. Going JJ, Anderson TJ, Wyllie AH: Ras p21 in breast tissue: associations with pathology and cellular localisation. Br J Cancer 65: 45-50, 1992.
20. Pechoux C, Chardonnet Y, Chignol MC, Noel P: Heterogeneous immunoreactivity of frozen human benign and malignant breast lesions to c-myc and c-Ha-ras celli lar oncogenes. Histol Histopathol 9: 35-44, 1994.
21. Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075-6086, 1990.
22. Pauley RJ, Soule HD, Tait L, Miller FR, Wolman SR, Dawson PJ, Heppner GH: The MCF10 family of spontaneously immortalized human breast epithelial cell lines: models of neoplastic progression. Eur J Cancer Prev 2 Suppl 3: 67-76, 1993.
23. Wolman SR, Mohamed AN, Heppner GH, Soule HD: Chromosomal markers of immortalization in human breast epithelium. Genes, Chromosomes, & Cancer 10: 59-65, 1994.
24. Miller, F.R Pauley, R.J and Wang, B. Activated c-Ha-ras is not sufficient to produce the preneoplastic phenotype of human breast cell line MCF10AT. AntiCancer Res 16: 1765-1770, 1996.
25. Miller FR, Soule HD, Tait L, Pauley RJ, Wolman SR, Dawson PJ, Heppner GH: Xenograft model of human proliferative breast disease. J Natl Cancer Inst 85: 1725-1732, 1993.
26. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR: MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 148: 313-319, 1996.
27. Tait L, Dawson PJ, Wolman SR, Miller FR: Multipotent human breast stem cell line MCF10AT. Int J Oncol 9: 263-267, 1996.
28. Tait L, Dawson PJ, Miller FR: Detection of micro invasion during progression in preneoplastic human breast xenograft model. Int J Oncol 8: 1113-1117, 1996.
29. Basolo F, Elliott J, Tait L, Chen XQ, Maloney T, Russo IH, Pauley R, Momiki S, Caamano J, Klein-Szanto AJP, Koszalka M, Russo J: Transformation of human breast epithelial cells by c-Ha-ras oncogene. Mol Carcinogen 4: 25-35, 1991.
30. Kang JS, Krauss R: Ras induces anchorage-independent growth by subverting multiple adhesion-regulated cell cycle events. Mol Cell Biol 16: 3370-3380, 1996.
31. Muschel R Williams JE, Lowy DR, Liotta LA: Harvey Ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell. Am J Pathol 121: 1-8, 1985.
32. Albini A, Graf J, Kitten GT, Kleinman HK, Martin GR, Veillette A, Lippman ME: 17 -estradiol regulates and v-Ha-ras transfection constitutively enhances MCF7 breast cancer cell interactions with basement membrane. Proc Natl Acad Sci U.S.A. 83: 8182-8186, 1986.
33. Sukumar S, Carney WP, Barbacid M: Independent molecular pathways in initiation and loss of hormone responsiveness of breast carcinomas. Science 240: 524-526, 1988.